CNBC's Jim Cramer talks about small-cap biotech company Kura Oncology and analyzes the company's stock performance. Got a confidential news tip? We want to hear from you. Sign up for free newsletters ...
Good day, everyone. My name is Abigail, and I will be your conference operator today. At this time, I would like to welcome you to the Kura ASH 2025 Update Call. [Operator Instructions] At this time, ...
Kura Oncology is rated a cautious Speculative Buy, driven by Komzifti's FDA approval and frontline AML potential. KURA's near-term revenue under the current label is meaningful but insufficient to ...
Kura Oncology remains a Strong Buy, driven by Ziftomenib's differentiated safety profile and significant AML market potential. KURA's Ziftomenib avoids a QTc prolongation boxed warning, offering a ...
Hosted on MSN
Kura Oncology Announces First U.S. Sale of KOMZIFTI
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
At this time, I would like to welcome you to the Kura Oncology FDA approval conference call. [Operator Instructions] At this time, I would like to turn the call over to Greg Mann from Kura Oncology.
The average one-year price target for Kura Oncology (NasdaqGS:KURA) has been revised to $31.53 / share. This is an increase of 14.48% from the prior estimate of $27.54 dated November 7, 2025. The ...
Nov 13 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Kura Oncology (KURA.O), opens new tab and Japanese partner Kyowa Kirin's (4151.T), opens new tab once-daily pill, Komzifti ...
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has ...
The U.S. Food and Drug Administration on Thursday approved ziftomenib (Komzifti), a leukemia drug developed by Kura Oncology (KURA) with Japanese drugmaker Kyowa Kirin (OTCPK:KYKOF) (OTCPK:KYKOY), ...
Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a subset of patients with acute myeloid leukemia. On Thursday, the FDA signed off ...
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2025 Earnings Call Transcript November 4, 2025 Kura Oncology, Inc. misses on earnings expectations. Reported EPS is $-0.84564 EPS, expectations were $-0.57.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results